Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Retrieved March 28, 2026
How many people take GLP-1 medications in the United States
In the UK, each medical condition has an official code from the World Health Organization (WHO), International Classification of Diseases (ICD) currently under 10th revision thus, an ICD-10 code
Unlike earlier-generation weight-management agents, retatrutide is a triple receptor agonist , meaning it simultaneously activates three distinct hormonal receptors: GLP-1 (glucagon-like peptide-1) receptor promotes insulin secretion, reduces appetite, and slows gastric emptying [9] [10] GIP (glucose-dependent insulinotropic polypeptide) receptor enhances insulin release and may improve fat metabolism [12] [13] Glucagon receptor increases energy expenditure and may reduce hepatic steatosis, as suggested by imaging data (MRI-PDFF) from Phase 2 trials, though this effect requires confirmation in larger studies [2] [5] This triple-agonist mechanism distinguishes retatrutide from agents such as semaglutide (GLP-1 only) or tirzepatide (GLP-1/GIP dual agonist), and is thought to produce more pronounced reductions in body weight and improvements in metabolic parameters
Other Potential Risks Tirzepatide can, in some cases, cause low blood sugar (hypoglycemia)
US$ 24.92
US$ 22.59
US$ 20.35
